BAYRY
💰 Bayer’s acquisition of Monsanto at $128 per share is analyzed as a potential opportunity.
⚠️ The deal faces antitrust concerns, with the market pricing Monsanto shares lower due to uncertainty.
✅ If the deal succeeds, investors could see a 23% return by late 2017.
🛡️ If the deal fails, Monsanto remains a strong company with competitive advantages in patents and innovation.
@emeritoquintana:
“Bayer is set to acquire Monsanto for $128 per share, totaling $66 billion. Post-acquisition, Bayer will be heavily indebted, approximately 3.6 times its net debt to EBITDA, requiring significant debt repayment efforts. The market is skeptical about the deal’s approval due to antitrust issues, reflected in Monsanto’s stock price hovering around $104. If the deal proceeds, investors could gain about 23% by the end of 2017. Even if the deal falls through, Monsanto remains a solid company with strong competitive advantages in patents and innovation, acquired at a fair price.”
Watch the exact part of the video where Emérito talks about Bayer here:
Watch the video on YouTube.
Read more articles by the world’s top 100 analysts on Bayer (BAYRY) at the following link. BAYRY stock.
